Xenetic Biosciences, Inc. (XBIO)
NASDAQ: XBIO · Real-Time Price · USD
1.720
-0.210 (-10.88%)
At close: Oct 23, 2026, 4:00 PM EDT
1.700
-0.020 (-1.16%)
After-hours: Oct 23, 2026, 4:00 PM EDT
Xenetic Biosciences Revenue
Xenetic Biosciences had revenue of $660.60K in the quarter ending June 30, 2026, with 11.99% growth. This brings the company's total for the last twelve months to $3.26M, up 33.30% year-over-year. In the year 2025, Xenetic Biosciences had annual revenue of $2.98M with 19.04% growth. That makes Xenetic Biosciences the 41,216th largest company in the world by revenue and 5,543rd in the United States.
Revenue (ttm)
$3.26M
Revenue Growth
+33.30%
P/S Ratio
1.24
Revenue / Employee
$1,630,389
Employees
2
Market Cap
4.03M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.98M | 476.13K | 19.04% |
| Dec 31, 2024 | 2.50M | -39.70K | -1.56% |
| Dec 31, 2023 | 2.54M | 833.06K | 48.80% |
| Dec 31, 2022 | 1.71M | 546.23K | 47.06% |
| Dec 31, 2021 | 1.16M | 723.75K | 165.64% |
| Dec 31, 2020 | 436.94K | 419.88K | 2,460.31% |
| Dec 31, 2019 | 17.07K | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | 7.59M | 4.59M | 152.83% |
| Dec 31, 2016 | 3.00M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 1.00M | 706.40K | 240.60% |
| Dec 31, 2012 | 293.60K | - | - |
| Aug 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Longeveron | 1.19M |
| Lexaria Bioscience | 194.00K |
| AIM ImmunoTech | 95.00K |
| Cardio Diagnostics Holdings | 14.45K |
| Azitra | 7.50K |
| Creative Medical Technology Holdings | 3.00K |
| Pulmatrix | 3.00K |
XBIO News
- 9 days ago - Xenetic, PeriNess announce first patient dosed in DNase with CAR T cells study - TheFly
- 9 days ago - Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma - Accesswire
- 5 weeks ago - Xenetic Biosciences Transcript: M&A announcement - Transcripts
- 5 weeks ago - Xenetic Biosciences Press release: M&A announcement - Filings
- 5 weeks ago - Xenetic Biosciences Slides: M&A announcement - Filings
- 5 weeks ago - Xenetic, Santerus enter definitive share exchange agreement - TheFly
- 5 weeks ago - Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics - Accesswire
- 5 weeks ago - Xenetic Biosciences Slides: Investor presentation - Filings